Blackfield Announces Fourth Major Pharmaceutical Company Collaboration

Blackfield has entered a collaboration with AstraZeneca, a global biopharmaceutical company. Under the terms of the agreement, Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of one of AstraZeneca’s oncology drug development programmes.

The collaboration with AstraZeneca marks Blackfield’s fourth partnership with a major pharmaceutical company within one year of starting up. Earlier this year Blackfield entered service agreements with Janssen Pharmaceuticals, Inc. (a division of Johnson & Johnson), Merck KGaA and Boehringer Ingelheim.

Professor Roman Thomas, Blackfield’s Scientific Director said: “We are pleased to help AstraZeneca make more informed decisions in the clinical stage of their compound development. By applying our unique background in genomics, cancer medicine, and computational biology, Blackfield mines genomic information to support our clients in developing targeted cancer therapies. We are delighted that Blackfield’s position as a preferred scientific partner for global pharma companies has been confirmed this quickly. It demonstrates that our science-driven partnering approach that leverages genome analysis and oncology experience to offer expertise from one source is of highest value to the pharmaceutical industry.”

www.blackfield.de